A specialty pharma firm which supports oncology care, Midatech pharma US Inc. made an announcement today that it has changed its name to Fortovia Therapeutics Inc. formally.
To increase their commitment with the patients and further the opportunities for growth, the specialty pharma firm has made 2 long-term executive appointments in order to reinforce its leadership team. Ernest De Paolantonio joined the firm as the Chief Financial Officer, whereas, the new Chief Executive Officer of the company will be Peter Melnyk who will be bringing with him an experience of more than 25 years in the field of oncology.
Before joining the Fortovia, Melnyk has been the Chief Commercial Officer at Novocure Inc. where he was responsible for managing the global sales, as well as, marketing efforts. He was also the Senior VP for the international sales & marketing at OSI Pharamceuticals Inc. In addition to this, Mr. Melnyk was the prior Executive Director at Pfizer Inc. and Director of Oncology, Bristol-Myers Squibb. He started his career in the LEO Laboratories.
On the other hand, Mister De Paolantonio has the past experiencing serving as the Chief Financial Officer of the BioDelivery Sciences International. At BioDelivery Sciences International, he was responsible for leading the finance organization and led the supply chain function as well. He has a strong history of working with private, as well as, with public pharmaceutical firms which have experienced swift growth.
Chairman of the Board at Fortovia, Michael Baumstein stated that his company was incredibly delighted about the growth opportunities, as well as, extra investment in oncology. He told that the team at Fortovia was pleased to make an announcement regarding the new leadership and was affirmative of hiring successful leaders.